Your browser doesn't support JavaScript. Please upgrade to a modern browser or enable JavaScript in your existing browser.
Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
www.ahrq.gov

Table 3. Abbreviated Evidence Table of Effects of Fluoride Varnish on Primary Teeth

Study, year Country Design Age at baseline Fluoride interventions Other F exposure Blinding Attrition, % Sample size, n % Reductiona, index used NNT
Experiment Control
Holm, 197939 Sweden RCT, 2 y, alternate assignment 3.0 2.2% F Duraphat®
2/y
71% F dentifrice,
27% F tabs
Patients 10 113 112 44**, defs 1.2
Grodzka, 198240 Poland Comparison schools, 2 y, assignment unclear 3.5 2.2% F Duraphat®
2/y
"low" F exposure, no professional F application None 20 100 148 5, dmfs1  
Frostell, 199141 Sweden RCT, 2 y 4.0 2.2% F Duraphat® w/wo invert sugar 2/y "most" use F dentifrice, "occasional" use of F supplements and mouth rinse Examiners Not reported 26 (sucrose)
18 (invert)
113 (neither)
37
33
93
+31, dmfs2
+50, dmfs2
30, dmfs2
37**, dmfs1



1.5
Twetman, 199642 Sweden Comm trial, 2 y, public clinics matched on SES 4.5 0.1% F Fluor  Protector® 2/y 0.1 ppm F in water,
95% on F dentifrice, "a few" given F supplements
None 2 374 442 30*, dfs 4.3
Petersson, 199843 Sweden Comm trial, 2 y, public clinics matched on specified criteria 4.5 0.1% F Fluor  Protector® 2/y 10% with 1.2 ppm in water, 90% use F dentifrice None 19 1,916 2,245  6, dfs NR
Autio-Gold, 200144 United States RCT,  0.75 y 3-5 2.2% F Duraphat® 0.8 ppm F in water Patients 22 83 59 63*, dmfs1
67**, dmfs2
0.8

aDifferences not significant unless otherwise noted.
*Different from control at P < 0.05.
**Different from control at P < 0.01.

Note: Comm indicates community; defs, decayed, extracted, and filled primary tooth surfaces; dfs, decayed, filled primary tooth surfaces; dmfs1, decayed, missing, and filled primary tooth surfaces, incipient lesions excluded; dmfs2, decayed, missing, and filled primary tooth surfaces, incipient lesions included; F, fluoride; NNT, number needed to treat; ppm, parts per million; RCT, randomized controlled trial; SES, socioeconomic status; w/wo, with or without.

Return to Document

 

AHRQ Advancing Excellence in Health Care